-
FDA approves drug for adults with rare form of bone marrow disorder
Market news
FDAMarch 02, 2022
FDA has granted accelerated approval for Vonjo (pacritinib) capsules to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis...
-
BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development
Market news
b3cnewswireMarch 01, 2022
German independent research institute BioMed X announces today the start of its new research project ‘Advanced Biomarker Detection for Pharmacological...
-
Approved first generic for Apokyn injection cartridges requires separately packaged pen
Market news
FDAFebruary 28, 2022
The U.S. Food and Drug Administration has approved the first generic of Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility “off” episodes...
-
FDA Approves Treatment for Wider Range of Patients with Heart Failure
Market news
FDAFebruary 25, 2022
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
-
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
Market news
PharmaSources.comFebruary 24, 2022
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
-
Q&M Dental records historic highest-ever revenue and profit after tax for year ended 31 December 2021 and declares a full year dividend yielding 7%
Market news
PharmaSources.comFebruary 24, 2022
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
-
V-01 as a Sequential Booster Can Produce Good Protection against Omicron ---- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma
Market news
PharmaSources.comFebruary 21, 2022
Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19.
-
Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Market news
PharmaSources.comFebruary 18, 2022
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing...
-
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Market news
PharmaSources.comFebruary 18, 2022
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research...
-
IgY antibody technology against SARS-CoV-2 unveiled
Market news
PharmaSources.comFebruary 18, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily.
FDA has granted accelerated approval for Vonjo (pacritinib) capsules to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis...
German independent research institute BioMed X announces today the start of its new research project ‘Advanced Biomarker Detection for Pharmacological...
The U.S. Food and Drug Administration has approved the first generic of Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility “off” episodes...
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19.
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing...
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research...
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily.
Pharma Sources Insight JUNE2022
